

The subdivisions of this section are:

- References

## References

- Abrahamsen B, Eiken P, Eastell R. Cumulative alendronate dose and the long-term absolute risk of subtrochanteric and diaphyseal femur fractures: a register-based national cohort analysis. *J Clin Endocrinol Metab* 2010;95:5258-65.
- Adami S, Libanati C, Boonen S, et al. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing. *J Bone Joint Surg Am* 2012;94:2113-19.
- Adler RA, El-Hajj Fuleihan G, Bauer DC, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American society for bone and mineral research. *J Bone Miner Res* 2016;31:16-35.
- Alekel DL, St Germain A, Peterson CT, et al. Isoflavone-rich soy protein isolate attenuates bone loss in the lumbar spine of perimenopausal women. *Am J Clin Nutr* 2000;72:844-52.
- Alexandersen P, Toussaint A, Christiansen, et al. for the Ipriflavone Multicenter European Fracture Study. Ipriflavone in the treatment of postmenopausal osteoporosis: a randomized controlled trial. *JAMA* 2001;285:1482-88.
- Anastasilakis AD, Polyzos SA, Makras P, et al. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. *J Bone Miner Res* 2017.
- Andrews EB, Gilsenan AW, Midkiff K, et al. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. *J Bone Miner Res* 2012;27:2429-37.
- Aris RM, Lester GE, Renner JB, et al. Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation. *Am J Respir Crit Care Med* 2000;162:941-46.
- Baim S, Binkley N, Bilezikian JP, et al. Official positions of the international society for clinical densitometry and executive summary of the 2007 ISCD position development conference. *J Clin Densitom* 2008;11:75-91.
- Behre HM, Kliesch S, Leifke E, et al. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. *J Clin Endocrinol Metab* 1997;82:2386-90.
- Bemben DA. Exercise interventions for osteoporosis prevention in postmenopausal women. *J Oklahoma State Med Assoc* 1999;92:66-70.
- Binkley N, Bilezikian JP, Kendler DL, et al. Official positions of the international society for clinical densitometry and executive summary of the 2005 position development conference. *J Clin Densitom* 2006;9:4-14.
- Bischoff-Ferrari HA, Willett WC, Wong JB, et al. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. *JAMA* 2005;293:2257-64.
- Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. *Lancet* 1996;348:1535-41.
- Black DM, Delmas PD, Eastell R, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. *N Engl J Med* 2007;356:1809-22.
- Black DM, Reid IR, Cauley JA, et al. The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: a randomized second extension to the HORIZON-Pivotal Fracture Trial (PFT). *J Bone Miner Res* 2015;30:934-44.

## References

- Black DM, Schwartz AV, Ensrud KE, et al. Effects of continuing or stopping alendronate after 5 years of treatment: the fracture intervention trial long-term extension (FLEX): a randomized trial. *JAMA* 2006;296:2927-38.
- Black DM, Thompson DE, Bauer DC, et al. Fracture risk reduction with alendronate in women with osteoporosis: the fracture intervention trial. *J Clin Endocrinol Metab* 2000;85:4118-24.
- Bolland MJ, Barber PA, Doughty RN, et al. Vascular events in healthy older women receiving calcium supplementation: randomised controlled trial. *BMJ* 2008;336:262-66.
- Bonnick SL. *In Bone Densitometry in Clinical Medicine*. Chapter 9: Clinical Indications for Bone Densitometry, Totowa NJ: Humana Press, 1998:197-210.
- Boonen S, Lorenc RS, Wenderoth D, et al. Evidence for safety and efficacy of risedronate in men with osteoporosis over 4 years of treatment: results from the 2-year, open-label, extension study of a 2-year, randomized, double-blind, placebo-controlled study. *Bone* 2012;51:383-88.
- Boonen S, Orwoll E, Magaziner J, et al. Once-yearly zoledronic acid in older men compared with women with recent hip fracture. *JAGS* 2011;59:2084-90.
- Branca F. Physical activity, diet and skeletal health. *Public Health Nutr* 1999;2:391-96.
- Chandler JM, Zimmerman SI, Girman CJ, et al. Low bone mineral density and risk of fracture in white female nursing home residents. *JAMA* 2000;284:972-77.
- Chapuy MC, Arlot ME, Duboeuf F, et al. Vitamin D<sub>3</sub> and calcium to prevent hip fractures in elderly women. *N Engl J Med* 1992;327:1637-42.
- Chen L, Wang G, Zheng F, et al. Efficacy of bisphosphonates against osteoporosis in adult men: a meta-analysis of randomized controlled trials. *Osteoporos Int* 2015;26:2355-63.
- Chesnut CH, Ettinger MP, Miller PD, et al. Ibandronate produces significant, similar antifracture efficacy in North American and European women: new clinical findings from BONE. *Current Med Research & Opinion* 2005;21:391-401.
- Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study (PROOF). *Am J Med* 2000;109:267-76.
- Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. *J Bone Miner Res* 2004;19:1241-49.
- Cockayne S, Adamson J, Lanham-New S, et al. Vitamin K and the prevention of fractures: systematic review and meta-analysis of randomized controlled trials. *Arch Intern Med* 2006;166:1256-61.
- Cohen S, Levy RM, Keller M, et al. Risedronate therapy prevents corticosteroid induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum* 1999;42:2309-18.
- Cooper A, Drake J, Brankin E. Treatment persistence with once-monthly ibandronate and patient support versus once-weekly alendronate: results from the PERSIST study. *Int J Clin Pract* 2006;8:896-905.
- Cornuz J, Feskanich D, Willett WC, Colditz GA. Smoking, smoking cessation, and risk of hip fracture in women. *Am J Med* 1999;106:311-14.
- Cosman F, de Beur SJ, LeBoff MS, et al. Clinician's guide to prevention and treatment of osteoporosis. *Osteoporos Int* 2014;25:2359-81.
- Cramer JA, Amonkar MM, Hebborn A, Altman R. Compliance and persistence with bisphosphonate dosing regimens among women with postmenopausal osteoporosis. *Curr Med Res Opin* 2005;21:1453-60.

## References

- Cramer JA, Silverman S. Persistence with bisphosphonate treatment for osteoporosis: finding the root of the problem. *Am J Med* 2006;119:12S-17S.
- Crawford BAL, Kam C, Pavlovic J, et al. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind placebo-controlled trial. *Ann Intern Med* 2006;144:239-48.
- Cumming RG, Nevitt MC. Calcium for prevention of osteoporotic fractures in postmenopausal women. *J Bone Miner Res* 1997;12:1321-29.
- Cummings SR, Nevitt MC, Browner WS, et al. Risk factors for hip fracture in white women. *N Engl J Med* 1995;332:767-73.
- Cummings SR, San Martin J, McClung MR, et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. *N Engl J Med* 2009;361:756-65.
- Cummings SR, Schwartz AV, Black DM. Alendronate and atrial fibrillation. *N Engl J Med* 2007;356:1895-96.
- Dawson-Hughes B, Dallal GE, Krall EA, et al. A controlled trial of the effect of calcium supplementation on bone density in postmenopausal women. *N Engl J Med* 1990;323:878-83.
- Dawson-Hughes B, Harris SS, Krall EA, Dallal GE. Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. *N Engl J Med* 1997;337:670-76.
- Delmas PD, Adami S, Strugala C, et al. Intravenous ibandronate injections in postmenopausal women with osteoporosis: one-year results from the dosing intravenous administration study. *Arthritis Rheum* 2006;54:1838-46.
- Donaldson MG, Palermo L, Ensrud K, et al. Effect of alendronate for reducing fracture by FRAX<sup>®</sup> score and femoral neck bone mineral density: the fracture intervention trial. *J Bone Miner Res* 2012;27:1804-10.
- Eastell R, Barton I, Hannon RA, et al. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. *J Bone Miner Res* 2003;18:1051-56.
- Ebeling PR. Transplantation osteoporosis. *Curr Osteoporos Rep* 2007;5:29-37.
- Eisman JA, Civitelli R, Adami S, et al. Efficacy and tolerability of intravenous ibandronate injections in postmenopausal osteoporosis: 2-year results from the DIVA study. *J Rheumatol* 2008;35:488-97.
- Emaus N, Gjesdal CG, Almås B, et al. Vitamin K2 supplementation does not influence bone loss in early menopausal women: a randomised double-blind placebo-controlled trial. *Osteoporos Int* 2010;21:1731-40.
- Emkey R, Koltun W, Beusterien K, et al. Patient preference for once-monthly ibandronate versus once-weekly alendronate in a randomized, open-label, cross-over trial: the Boniva Alendronate trial in osteoporosis (BALTO). *Curr Med Res Opin* 2005;21:1895-903.
- Ensrud K, Genazzani AR, Geiger MJ, et al. Effect of *raloxifene* on cardiovascular adverse events in postmenopausal women with osteoporosis. *Am J Cardiol* 2006;97:520-27.
- Eriksen EF, Díez-Pérez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review. *Bone* 2014;58:126-35.
- Ettinger B, Black DM, Mitlak BH, et al. for the Multiple Outcomes Raloxifene Evaluation (MORE) Investigators. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. *JAMA* 1999;282:637-45.
- Farsinejad-Marj M, Saneei P, Esmailzadeh A. Dietary magnesium intake, bone mineral density and risk of fracture: a systematic review and meta-analysis. *Osteoporos Int* 2016;27:1389-99.

## References

- Faulkner KG, VonStetten E, Miller P. Discordance in patient classification using T-scores. *J Clin Densitometry* 1999;2:343-50.
- Finkelstein JS, Hayes A, Hunzelman JL, et al. The effects of parathyroid hormone, alendronate, or both in men with osteoporosis. *N Engl J Med* 2003;349:1216-26.
- Fleischer J, McMahon DJ, Hembree W, et al. Serum testosterone levels after cardiac transplantation. *Transplantation* 2008;85:834-39.
- Fogelman I, Ribot C, Smith R, et al. Risedronate reverses bone loss in postmenopausal women with low bone mass: results from a multinational, double-blind, placebo-controlled trial. *J Clin Endocrinol Metab* 2000;85:1895-1900.
- Food and Drug Administration. Information on Miacalcin (calcitonin-salmon). Available at: <https://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm388640.htm>. 2015.
- Gallagher JC, Satpathy R, Rafferty K, Haynatzka V. The effect of soy protein isolate on bone metabolism. *Menopause* 2004;11:290-98.
- Glüer CC, Marin F, Ringe JD, et al. Comparative effects of teriparatide and risedronate in glucocorticoid-induced osteoporosis in men: 18-month results of the EuroGIOPs trial. *J Bone Miner Res* 2013;28:1355-68.
- Gourlay ML, Fine JP, Preisser JS, et al. Bone-density testing interval and transition to osteoporosis in older women. *N Engl J Med* 2012;366:225-33.
- Hailey D, Sampietro-Colom L, Marshall D, et al. The effectiveness of bone density measurement and associated treatments for prevention of fractures: an international collaborative review. *Int J Tech Assess Health Care* 1998;14:237-54.
- Hamdy NAT. Calcium and bone metabolism pre- and post-kidney transplantation. *Endocrinol Metal Clin N Am* 2007;36:923-35.
- Hannan MT, Felson DT, Dawson-Hughes B, et al. Risk factors for longitudinal bone loss in elderly men and women: The Framingham Osteoporosis Study. *J Bone Miner Res* 2000;15:710-20.
- Hans DB, Kanis JA, Baim S, et al. Joint official positions of the international society for clinical densitometry and international osteoporosis foundation on FRAX®. *J Clin Densitom* 2011;14:171-80.
- Harris ST, Watts NB, Genant HK, et al. for the Vertebral Efficacy with Risedronate Therapy (VERT) study group. Effects of risedronate treatment on vertebral and non-vertebral fractures in women with postmenopausal osteoporosis. *JAMA* 1999;282:1344-52.
- Heaney RP. Calcium, dairy products and osteoporosis. *J Am Coll Nutr* 2000;19:83S-99S.
- Heckbert SR, Li G, Cummings SR, et al. Use of alendronate and risk of incident atrial fibrillation in women. *Arch Intern Med* 2008;168:826-31.
- Heller HJ, Stewart A, Haynes S, Pak CYC. Pharmacokinetics of calcium absorption from two commercial calcium supplements. *J Clin Pharmacol* 1999;39:1151-54.
- Hellstein JW, Adler RA, Edwards B, et al. Managing the care of patients receiving antiresorptive therapy for prevention and treatment of osteoporosis: executive summary of recommendations from the American dental association council on scientific affairs. *JADA* 2011;142:1243-51.
- Ho SC, Chan SG, Yi Q, et al. Soy intake and the maintenance of peak bone mass in Hong Kong Chinese women. *J Bone Miner Res* 2001;16:1363-69.

## References

- Hochberg MC, Ross PD, Black D, et al. for the Fracture Intervention Trial Research Group. Larger increases in bone mineral density during alendronate therapy are associated with a lower risk of new vertebral fractures in women with postmenopausal osteoporosis. *Arthritis Rheum* 1999;42:1246-54.
- Hodsman AB, Bauer DC, Dempster DW, et al. Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use. *Endocr Rev* 2005;26:688-703.
- Høidrup S, Grønbaek M, Gottschau A, et al. Alcohol intake, beverage preference, and risk of hip fracture in men and women. *Am J Epidemiol* 1999;149:993-1001.
- Horiuchi T, Onouchi T, Takahashi M, et al. Effect of soy protein on bone metabolism in postmenopausal Japanese women. *Osteoporos Int* 2000;11:721-24.
- Howard PA, Barnes BJ, Vacek JL, et al. Impact of bisphosphonates on the risk of atrial fibrillation. *Am J Cardiovasc Drugs* 2010;10:359-67.
- Huopio J, Kroger H, Honkanen R, et al. Risk factors for perimenopausal fractures: a prospective study. *Osteoporos Int* 2000;11:219-27.
- Institute of Medicine. Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D and fluoride. Washington, DC: National Academy Press, 1997. Available at: <http://www.nap.edu/books/0309071836/html/>.
- International Society for Clinical Densitometry, The. *In 2007 Official Positions of the International Society for Clinical Densitometry*. October 2007.
- International Society for Clinical Densitometry, The. Official positions 2015 ISCD combined: official positions of the international society for clinical densitometry. Available at: [www.ISCD.org](http://www.ISCD.org). June 2015.
- Kanis JA, Delmas P, Burckhardt P, et al. on behalf of the European Foundation for Osteoporosis and Bone Disease. Guidelines for diagnosis and management of osteoporosis. *Osteoporos Int* 1997;7:390-406.
- Katznelson L, Finkelstein JS, Schoenfeld DA, et al. Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. *J Clin Endocrinol Metab* 1996;81:4358-65.
- Klein RF. Alcohol-induced bone disease: impact of ethanol on osteoblast proliferation. *Alcohol Clin Exp Res* 1997;21:392-99.
- Knopp-Sihota JA, Newburn-Cook CV, Homik J, et al. Calcitonin for treating acute and chronic pain of recent and remote osteoporotic vertebral compression fractures: a systematic review and meta-analysis. *Osteoporos Int* 2012;23:17-38.
- Komulainen M, Tuppurainen MT, Kroger H, et al. Vitamin D and HRT: no benefit additional to that of HRT alone in prevention of bone loss in early postmenopausal women: a 2.5 year randomized placebo-controlled study. *Osteoporos Int* 1997;7:126-32.
- Kopecky SL, Bauer DC, Gulati M, et al. Lack of evidence linking calcium with or without vitamin D supplementation to cardiovascular disease in generally healthy adults: a clinical guideline from the national osteoporosis foundation and the American society for preventive cardiology. *Ann Intern Med* 2016;165:867-68.
- Kothawala P, Badamgarav E, Ryu S, et al. Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. *Mayo Clin Proc* 2007;82:1493-1501.
- Kreijkamp-Kaspers S, Kok L, Grobbee DE, et al. Effect of soy protein containing isoflavones on cognitive function, bone mineral density, and plasma lipids in postmenopausal women: a randomized controlled trial. *JAMA* 2004;292:65-74.

## References

- Layne JE, Nelson ME. The effects of progressive resistance training on bone density: a review. *Med Sci Sports Exerc* 1999;31:25-30.
- LeBoff MS, Kohlmeier L, Hurwitz S, et al. Occult vitamin D deficiency in postmenopausal U.S. women with acute hip fracture. *JAMA* 1999;281:1505-11.
- Leonetti HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. *Obstet Gynecol* 1999;94:225-28.
- Lipworth BJ. Systemic adverse effects of inhaled corticosteroid therapy. A systematic review and meta-analysis. *Arch Intern Med* 1999;159:941-55.
- Liu J, Ho SC, Su YX, et al. Effect of long-term intervention of soy isoflavones on bone mineral density in women: a meta-analysis of randomized controlled trials. *Bone* 2009;44:948-53.
- Looker AC, Borrud LG, Dawson-Hughes B, et al. Osteoporosis or low bone mass at the femur neck or lumbar spine in older adults: United States, 2005-2008. *NCHS Data Brief* 2012;(93):1-8.
- Lung Health Study Research Group, The. Effect of inhaled triamcinolone on the decline of pulmonary function in chronic obstructive pulmonary disease. *N Engl J Med* 2000;343:1902-09.
- Lydeking-Olsen E, Beck-Jensen JE, Setchell KD, Holm-Jensen T. Soymilk or progesterone for prevention of bone loss – a 2 year randomized, placebo-controlled trial. *Eur J Nutr* 2004;43:246-57.
- Lyles KW, Colón-Emeric CS, Magaziner JS, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. *N Engl J Med* 2007;357:1799-809.
- Maalouf NM, Shane E. Clinical review: osteoporosis after solid organ transplantation. *J Clin Endocrinol Metab* 2005;90:2456-65.
- McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. *N Engl J Med* 2001;344:333-40.
- McClung MR, Wagman RB, Miller PD, et al. Observations following discontinuation of long-term denosumab therapy. *Osteoporos Int* 2017.
- Miller PD, Bonnick SL. Clinical application of bone densitometry. *In Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism*. Philadelphia: Lippincott Williams and Wilkins, 1999: 152-59.
- Miller PD, Hattersley G, Riis BJ, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. *JAMA* 2016;316:722-33.
- Miller PD, McClung MR, Macovei L, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. *J Bone Miner Res* 2005;20:1315-22.
- Miller PD, Recker RR, Reginster JY, et al. Efficacy of monthly oral ibandronate is sustained over 5 years: the MOBILE long-term extension study. *Osteoporos Int* 2012;23:1747-56.
- National Osteoporosis Foundation. *In Clinician's Guide to Prevention and Treatment of Osteoporosis*. Washington DC: National Osteoporosis Foundation, 2010.
- Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. *N Engl J Med* 2001;344:1434-41.
- Nelson HD, Haney EM, Dana T, et al. Screening for osteoporosis: an update for the U.S. preventive services task force. *Ann Intern Med* 2010;153:99-111.
- NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. *JAMA* 2001;285:785-95.

## References

- O'Connell MB, Madden DM, Murray AM, et al. Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. *Am J Med* 2005;118:778-81.
- Orchard TS, Larson JC, Alghothani N, et al. Magnesium intake, bone mineral density, and fractures: results from the women's health initiative observational study. *Am J Clin Nutr* 2014;99:926-33.
- Orwoll E, Ettinger M, Weiss S, et al. Alendronate for the treatment of osteoporosis in men. *N Engl J Med* 2000;343:604-10.
- Orwoll ES, Miller PD, Adachi JD, et al. Efficacy and safety of a once-yearly i.v. infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study. *J Bone Miner Res* 2010;25:2239-50.
- Papapoulos S, Lippuner K, Roux C, et al. The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. *Osteoporos Int* 2015;26:2773-83.
- Pickar JH, Yeh IT, Bachmann G, Speroff L. Endometrial effects of a tissue selective estrogen complex containing bazedoxifene/conjugated estrogens as a menopausal therapy. *Fertil Steril* 2009;92:1018-24.
- Potter SM, Baum JA, Teng H, et al. Soy protein and isoflavones: their effects on blood lipids and bone density in postmenopausal women. *Am J Clin Nutr* 1998;68(suppl):1375S-79S.
- Prince RL, Smith M, Dick IM, et al. Prevention of postmenopausal osteoporosis: a comparative study of exercise, calcium supplementation, and hormone-replacement therapy. *N Engl J Med* 1991;325:1189-95.
- Ravn P, Cizza G, Bjarnason NH, et al. Low body mass index is an important risk factor for low bone mass and increased bone loss in early postmenopausal women. *J Bone Miner Res* 1999;14:1622-27.
- Recker RR, Gallagher R, MacCosbe PE. Effect of dosing frequency on bisphosphonate medication adherence in a large longitudinal cohort of women. *Mayo Clin Proc* 2005;80:856-61.
- Recker RR, Hinders S, Davies KM, et al. Correcting calcium nutritional deficiency prevents spine fractures in elderly women. *J Bone Miner Res* 1996;11:1961-66.
- Reid IR, Mason B, Horne A, et al. Effects of calcium supplementation on serum lipid concentrations in normal older women: a randomized controlled trial. *Am J Med* 2002;112:343-47.
- Riggs BL, O'Fallon WM, Muhs J, et al. Long-term effects of calcium supplementation on serum parathyroid hormone level, bone turnover, and bone loss in elderly women. *J Bone Miner Res* 1998;13:168-74.
- Ross EA, Szabo NJ, Tebbett IR. Lead content of calcium supplements. *JAMA* 2000;284:1425-29.
- Ruggiero SL, Dodson TB, Assael LA, et al. American association of oral and maxillofacial surgeons position paper on bisphosphonate-related osteonecrosis of the jaws – 2009 update. *J Oral Maxillofac Surg* 2009;67:2-12.
- Saag KG, Emkey R, Schnitzer TJ, et al. Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. *N Engl J Med* 1998;339:292-99.
- Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis. *N Engl J Med* 2007;357:2028-39.
- Sambrook PN. Anabolic therapy in glucocorticoid-induced osteoporosis. *N Engl J Med* 2007;357:2084-86.
- Schilcher J, Michaëlsson K, Aspenberg P. Bisphosphonate use and atypical fractures of the femoral shaft. *N Engl J Med* 2011;364:1728-37.



## References

- Schrøder HM, Petersen KK, Erlandsen M. Occurrence and incidence of the second hip fracture. *Clin Orthop* 1993;289:166-69.
- Serpa Neto A, Tobias-Machado M, Esteves MAP, et al. Bisphosphonate therapy in adults under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis* 2012;15:36-44.
- Setchell KD, Lydeking-Olsen E. Dietary phytoestrogens and their effect on bone: evidence from in vitro and in vivo, human observational, and dietary intervention studies. *Am J Clin Nutr* 2003;78:593S-609S.
- Shane E, Adesso V, Namerow PB, et al. Alendronate versus calcitriol for the prevention of bone loss after cardiac transplantation. *N Engl J Med* 2004;350:767-76.
- Shenoy S, Bedi R, Sandhu JS. Effect of soy isolate protein and resistance exercises on muscle performance and bone health of osteopenic/osteoporotic post-menopausal women. *J Women Aging* 2013;25:183-98.
- Shiraki M, Shiraki Y, Aoki C, Miura M. Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis. *J Bone Miner Res* 2000;15:515-21.
- Sinaki M, Brey RH, Hughes CA, et al. Significant reduction in risk of falls and back pain in osteoporotic-kypnotic women through a spinal proprioceptive extension exercise dynamic (SPEED) program. *Mayo Clin Proc* 2005;80:849-55.
- Sinaki M, Itoi E, Wahner HW, et al. Stronger back muscles reduce the incidence of vertebral fractures: a prospective 10-year follow-up of postmenopausal women. *Bone* 2002;30:836-41.
- Siris ES, Harris ST, Eastell R, et al. Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to evista (CORE) study. *J Bone Miner Res* 2005;20:1514-24.
- Siris ES, Harris ST, Rosen CJ, et al. Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and non-vertebral fractures from 2 U.S. claims databases. *Mayo Clin Proc* 2006;81:1013-22.
- Sørensen HT, Christensen S, Mehnert F, et al. Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study. *BMJ* 2008;336:784-85.
- Stein E, Ebeling P, Shane E. Posttransplantation osteoporosis. *Endocrinol Metab Clin N Am* 2007;36:937-63.
- Tai TY, Tsai KS, Tu ST, et al. The effect of soy isoflavone on bone mineral density in postmenopausal Taiwanese women with bone loss: a 2-year randomized double-blind placebo-controlled study. *Osteoporos Int* 2012;23:1571-80.
- Tauchmanová L, Colao A, Lombardi G, et al. REVIEW: bone loss and its management in long-term survivors from allogeneic stem cell transplantation. *J Clin Endocrinol Metab* 2007;92:4536-45.
- Torgerson DJ, Bell-Syer SEM. Hormone replacement therapy and prevention of non-vertebral fractures: a meta-analysis of randomized trials. *JAMA* 2001;285:2891-97.
- Torregrosa JV, Fuster D, Pedrosa S, et al. Weekly risedronate in kidney transplant patients with osteopenia. *Transpl Int* 2007;20:708-11.
- Trabulus S, Altiparmak MR, Apaydin S, et al. Treatment of renal transplant recipients with low bone mineral density: a randomized prospective trial of alendronate, alfacalcidol, and alendronate combined with alfacalcidol. *Transplant Proc* 2008;40:160-66.
- Ulrich CM, Georgiou CC, Gillis DE, Snow CM. Lifetime physical activity is associated with bone mineral density in postmenopausal women. *J Women Health* 1999;8:365-75.

**References**

---

U.S. Preventive Services Task Force. Screening for osteoporosis: U.S. preventive services task force recommendation statement. *Ann Intern Med* 2011;154:356-64.

Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP study of tamoxifen and raloxifene (STAR) P-2 trial. *JAMA* 2006;295:2727-41.

Weaver CM. Calcium requirements of physically active people. *Am J Clin Nutr* 72:579S-84S, 2000.

Women's Health Initiative, The. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women's health initiative randomized controlled trial. *JAMA* 2004;291:1701-12.

Wong CA, Walsh LJ, Smith JP, et al. Inhaled corticosteroid use and bone mineral density in patients with asthma. *Lancet* 2000;355:1399-1403.

Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women's health initiative randomized controlled trial. *JAMA* 2002;288:321-33.

Xu W, Perera S, Medich D, et al. Height loss, vertebral fractures, and the misclassification of osteoporosis. *Bone* 2011;48:307-11.

Yao S, McCarthy PL, Dunford LM, et al. High prevalence of early-onset osteopenia/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy. *Bone Marrow Transplant* 2008;41:393-98.

Yong G, Hayes H, O'Driscoll G. Strategy of aggressive steroid weaning and routine alendronate therapy to reduce bone loss after cardiac transplantation. *Transplant Proc* 2007;39:3340-43.